Harald Reinhart
Nessuna posizione attualmente
Patrimonio netto: 989 590 $ in data 31/05/2024
Storia della carriera di Harald Reinhart
Precedenti posizioni note di Harald Reinhart
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ZAI LAB LIMITED | Corporate Officer/Principal | 01/01/2017 | 30/06/2024 |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Corporate Officer/Principal | - | - |
Formazione di Harald Reinhart
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Statistiche
Distribuzione geografica
| Isole Cayman | 2 |
| Stati Uniti | 2 |
| Germania | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ZAI LAB LIMITED | Health Technology |
| Aziende private | 1 |
|---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
- Borsa valori
- Insiders
- Harald Reinhart
- Esperienza
